Ejko-Druk Janusz i Jolanta Klejmentsp. j.

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2001-06-12
Registered address
Wolska 3A, 05-119 Stanisławów II, Poland

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 2 of 6 financial statements were filed late (the longest delay 347 days for 2023).

  • 2025not filed
  • 202427/06/2025
  • 202327/06/2025
  • 202217/07/2023
  • 202121/06/2022
  • 202028/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Sector · Manufacturing378 / 881
Top 43%
Voivodeship · Mazowieckie71,235 / 142,033
Top 50%
Country · Poland257,375 / 495,860
Top 52%

Results vs industry

Revenue
This companyUSD 154.55kMedianUSD 154.55kAverageUSD 154.55k
Net profit
This companyUSD 18.81kMedianUSD 18.81kAverageUSD 18.81k
Operating costs
This companyUSD 116.09kMedianUSD 116.09kAverageUSD 116.09k
Assets
This companyUSD 260.55kMedianUSD 260.55kAverageUSD 260.55k

Industry

  • Manufacture of pulp, paper and paperboard (21.1)
  • Manufacture of articles of paper and paperboard (21.2)
  • Publishing activities (22.1)

Ownership

Owner
Janusz Jan Klejmentage 71
Jolanta Klejmentage 69

Manner of representation

Each partner independently.

Janusz Jan Klejment and Jolanta Klejment – all partners share the same surname, so the structure looks family-owned.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 1993-09-22.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

8 public aid cases recorded, with a total value of $5,034.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$323
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$323
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282

Competitors

Name
VercoS.A.
VipharmS.A.
MedicofarmaS.A.
VitamaS.A.
Biotriosp. z o.o.
Munar PharmaS.A.
Bioresearch PharmaS.A.
Sanford Biotechsp. z o.o.
Cefeasp. z o.o.
Auxilius PharmaS.A.

FAQ

Last updated: 2026-03-31